Lantheus Holdings

Lantheus Holdings

Pharmaceuticals
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

$6.6B

Market Cap • 11/5/2026

2007

(19 years)

Founded

2015

(11 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

4,9

P/S

4,2

P/EBITDA

17,2

P/OCF

16,1

P/FCF

16,8

P/E

24,8

BVPS

20,7

EPS

4

Market Cap

Market Cap

6,6B

EV

6,5B

EV/Revenue

4,1

EV/EBITDA

17

EV/EBIT

22,3

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

1,3%

Total Yield

1,3%

Payout

0%

Retained Earnings

895,3M

Profitability

Gross Margin

61,3%

EBITDA Margin

24,4%

EBIT Margin

18,6%

Net Margin

17,3%

D&A/EBITDA

0%

R&D/Revenue

13,9%

Capex/Revenue

1%

Capex/D&A

18%

Capex/OCF

4%

SBC/OCF

18,4%

% PPE

6,1%

% Goodwill

9,7%

ROE

21,8%

ROIC

15,4%

Growth

CAGR Revenue 5Y

32%

CAGR OCF 5Y

58,8%

Leverage

N.D./EBITDA

—

Debt/Equity

0%

Current Ratio

3,2

Quick Ratio

3

Interest Coverage

1469,6%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium